Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetic Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DNMT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DNMT1 Recombinant Protein (Wild-Type & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/Bac-to-Bac expressed for native post-translational modifications. |
View DNMT1 Products |
| Gene Delivery | DNMT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target engagement assays. |
View DNMT1 Products |
| Benchmark Ab | Anti-DNMT1 Recombinant Antibody Recombinant positive control for assay validation. |
View DNMT1 Products |
| Validator | DNMT1 siRNA Set For knockdown verification in target specificity studies. |
View DNMT1 Products |
| Related Target A | DNMT3A De novo DNA methyltransferase; critical for selectivity profiling to avoid off-target hematological toxicity. |
View DNMT3A Products |
| Related Target B | DNMT3B De novo DNA methyltransferase; essential counter-screening target for highly selective DNMT1 inhibitor development. |
View DNMT3B Products |
| Related Target C | UHRF1 Epigenetic coordinator that recruits DNMT1 to hemimethylated DNA; key target for protein-protein interaction (PPI) disruptors. |
View UHRF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling (DNMT1 vs. DNMT3A/3B) | Full panel of active human recombinant DNMT family proteins (DNMT1, DNMT3A, DNMT3B) with verified high purity (>95%). |
| High-throughput screening (HTS) reproducibility | Sf9 insect cell-expressed active DNMT1 ensuring native-like folding, post-translational modifications, and consistent enzymatic kinetics. |
| Lack of Controls | Clinical-grade sequence-derived recombinant benchmark antibodies included for assay standardization. |
| False Positives | Sequence-verified siRNA sets included for orthogonal target knockdown validation. |
Live DNMT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DNMT1 therapeutics is intensifying, with major players shifting focus from traditional nucleoside analogs to highly selective, non-nucleoside small molecule inhibitors and targeted protein degraders (PROTACs). As first-generation therapies like decitabine and azacitidine present limitations due to their DNA-incorporating mutagenic mechanisms, the next wave of R&D is targeting selective DNMT1 inhibition to achieve sustained epigenetic reprogramming without cytopenic toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | GlaxoSmithKline, Exscientia | AML, MDS, Solid Tumors | Enzymatic Inhibition Assay (Need active, high-purity WT DNMT1 protein) |
| PROTACs / Molecular Glues | Arvinas, Monte Rosa Therapeutics | Advanced Hematological Malignancies | Degradation & Binding Assays (Need pure DNMT1 and UHRF1 proteins) |
| Combination Therapies (w/ PD-1) | Merck, Bristol Myers Squibb | Refractory Solid Tumors | In vitro syngeneic models (Need mouse and human ortholog reagents) |